Core Viewpoint - The announcement from 德视佳 (01846) indicates a significant increase in the total number of ophthalmic surgeries performed in Q3 2025, reflecting a growing patient demand and improved overall performance [1] Group 1: Surgical Performance - The total number of ophthalmic surgeries conducted by the company in Q3 2025 reached 6,807, representing an approximate increase of 5.6% compared to the same period in 2024, where the number was 6,445 [1] - The growth in surgical numbers is primarily attributed to an increase in the volume of lens replacement surgeries and a recovery in laser surgery procedures [1] Group 2: Market Demand - The positive changes in surgical performance are indicative of a continuous rise in patient demand, which is expected to contribute to the overall performance enhancement of the company [1]

Core Viewpoint - The company reported a total of 6,807 ophthalmic surgeries in Q3 2025, representing an increase of approximately 5.6% compared to the same period in 2024, driven by a rise in lens replacement surgeries and a recovery in laser procedures [1] Summary by Category Company Performance - The total number of ophthalmic surgeries performed by the company in Q3 2025 was 6,807, up from 6,445 in Q3 2024 [1] - The growth in surgeries is attributed to an increase in lens replacement surgeries and a recovery in laser surgery volumes [1] Market Demand - The positive change in surgery numbers reflects a growing patient demand, contributing to the overall performance of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 自願公告 2025年第三季度的眼科手術總數 德視佳國際眼科有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願刊發 本公告。本公司董事（「董事」）會（「董事會」）謹此宣佈，根據本公司的初步統計 數據及本公司目前可得的資料，統計本集團於2025年7月1日至2025年9月30日期 間（「2025年第三季度」）進行的眼科手術（統稱「眼科手術」）總數。 於2025年第三季度，本集團進行的眼科手術總數為6,807例，較2024年同期增加 約5.6%（於2024年9月30日：6,445例）。有關增長主要是由於晶體置換手術數量 增加以及激光手術量恢復。該積極變化反映於2025年第三季度的患者需求不斷增 長，有助於提升整體表現。 本公告所載數字未經審核 ...

Group 1 - A block trade of 689,300 shares of Aier Eye Hospital was executed on November 13, with a transaction value of 8.7886 million yuan and a transaction price of 12.75 yuan, representing a premium of 3.57% over the closing price of the day [2][3] - In the last three months, Aier Eye Hospital has recorded a total of 7 block trades, with a cumulative transaction value of 70.7487 million yuan [2] - The closing price of Aier Eye Hospital on the day of the block trade was 12.31 yuan, reflecting a 0.24% increase, with a daily turnover rate of 0.61% and a total trading volume of 593 million yuan [2] Group 2 - The latest margin financing balance for Aier Eye Hospital is 2.544 billion yuan, with an increase of 8.6439 million yuan over the past five days, representing a growth rate of 0.34% [3] - Aier Eye Hospital Group was established on January 24, 2003, with a registered capital of 932,539.667 million yuan [3]

Core Insights - The 19th World Association of Eye Hospitals (WAEH) annual meeting was successfully held in Lausanne, Switzerland, and Paris, France, focusing on clinical innovations powered by artificial intelligence, talent cultivation in ophthalmology, and patient-centered high-quality eye care development models [1][6] - Aier Eye Hospital Group, as the only board member from China, was re-elected to the WAEH board, representing Chinese ophthalmology on the international stage [1][6] Group 1 - Aier Eye Hospital's experts presented innovative clinical practices and management models at the conference, showcasing the establishment of nearly 200 intravitreal injection centers and a digital follow-up system that enhances patient care [3] - The dry eye clinic's capabilities and standardized management were discussed, emphasizing the importance of specialized services in improving treatment efficiency and patient satisfaction [3] - Aier Eye Hospital received recognition for eight posters presented at the conference, with one project winning the "Best Poster Award" for its innovative training system in refractive surgery [4] Group 2 - The conference highlighted the increasing global influence of Chinese ophthalmology, with more institutions participating in international dialogues and sharing innovative practices, such as Shanghai's model for public health eye management [6] - Aier Eye Hospital has been actively promoting the sharing of Chinese ophthalmic experiences internationally since becoming a board member in 2021, and it successfully hosted the 18th WAEH annual meeting in Changsha, China [6] - The next WAEH annual meeting will be held in South America, with interest from various countries, including China, in hosting future events, reflecting the academic and industry value of the conference [7]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance meets expectations with steady revenue growth. For the first three quarters of 2025, the operating revenue reached 3.272 billion yuan, a year-on-year increase of 2.83%. In the third quarter alone, the operating revenue was 1.133 billion yuan, growing by 0.13% year-on-year. The overall gross margin remains stable, with a gross margin of 44.71% in Q3 2025, slightly down from 45.44% in Q2 2025. Future growth in gross margin is anticipated as the company continues to focus on high-quality services, awaiting a return to higher revenue growth rates [5][11]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported an operating revenue of 3.272 billion yuan, up 2.83% year-on-year, and a net profit attributable to shareholders of 434 million yuan, an increase of 3.04%. In Q3 2025, the operating revenue was 1.133 billion yuan, with a net profit of 152 million yuan, down 2.37% year-on-year [5][11]. Strategic Initiatives - The company adheres to a dual-driven strategy of "internal growth + external mergers and acquisitions." It leverages the Xiamen Eye Center as a core, utilizing its leading diagnostic and treatment capabilities along with mature hospital management experience. The company has established a standardized high-quality medical service and management system across its chain of hospitals, expanding its ophthalmology network to 64 specialized hospitals and 67 optical centers across 19 provinces and municipalities by mid-2025 [11]. Research and Development - The company emphasizes the "coordinated development of medicine, education, and research," focusing on eye disease treatment. It has established a comprehensive medical education and research system, collaborating with over 40 universities, including Peking University and Xiamen University. This collaboration covers talent training, academic co-construction, and clinical research, with over 380 national and provincial research projects initiated and 1,641 academic papers published by mid-2025 [11]. Profit Forecast and Investment Advice - The company is projected to achieve net profits attributable to shareholders of 540 million yuan, 640 million yuan, and 730 million yuan for 2025, 2026, and 2027, respectively. The current stock price corresponds to price-to-earnings ratios of 30, 25, and 22 times for the respective years, maintaining a "Buy" rating [11].

Investment Rating - The investment rating for the company is "Recommended" (maintained) [1][6]. Core Insights - The company's revenue for the first three quarters of 2025 reached 2.201 billion yuan, a year-on-year increase of 2.99%, while the net profit attributable to the parent company was 16 million yuan, up 3.21% year-on-year. In Q3 alone, revenue was 741 million yuan, reflecting a year-on-year growth of 3.48%, and net profit attributable to the parent company surged by 106.13% to 2 million yuan [3][6]. - The company has improved its profitability, with a gross margin of 37.08% in Q3, up 1.12 percentage points year-on-year, and a net margin of 0.51%, an increase of 4 percentage points year-on-year. The management expenses have significantly decreased, contributing to this improvement [6]. - The company is gradually entering a performance release period with its newly established hospitals, having invested in 36 eye hospitals and 4 outpatient departments across over 20 cities by June 30, 2025. This expansion is expected to support sustained growth in performance as new hospitals mature [6]. Financial Projections - The company is expected to achieve net profits of 52 million yuan, 146 million yuan, and 246 million yuan for the years 2025 to 2027, respectively, reflecting adjustments from previous forecasts [6]. - Revenue projections for the years 2024 to 2027 are 2.678 billion yuan, 2.761 billion yuan, 2.946 billion yuan, and 3.267 billion yuan, with year-on-year growth rates of -1.5%, 3.1%, 6.7%, and 10.9% respectively [5][8]. - The gross margin is projected to be 37.0% in 2024, decreasing to 32.4% in 2025, and then recovering to 35.3% and 37.1% in 2026 and 2027, respectively [8]. Financial Ratios - The company’s asset-liability ratio is projected to decrease from 53.9% in 2024 to 32.6% in 2027, indicating improved financial stability [8]. - The return on equity (ROE) is expected to recover from -4.8% in 2024 to 10.2% in 2027, reflecting a significant turnaround in profitability [8]. - The earnings per share (EPS) is projected to be -0.68 yuan in 2024, turning positive to 0.35 yuan in 2025, and reaching 1.65 yuan by 2027 [8].

Core Viewpoint - The article emphasizes the importance of long-term commitment and focus in the healthcare industry, particularly in the context of Alcon's operations in China, highlighting its 30-year journey and dedication to eye health [1][27]. Group 1: Long-term Commitment and Focus - Alcon's long-termism is not just an abstract concept but a practical path that has been followed for 80 years globally and 30 years in China, focusing solely on ophthalmology [1][27]. - The "Phaco Development Project," initiated in 2008, exemplifies Alcon's commitment to long-term education and collaboration, having trained a significant portion of cataract surgeons in China [3][5]. - The project has evolved into a comprehensive system that includes technical empowerment, surgical standards, and academic education, reflecting Alcon's focus on deepening its impact in the eye health sector [3][5]. Group 2: Innovation and Collaboration - Alcon has transitioned from being an "innovative introducer" to a "collaborative builder" in the Chinese market, actively fostering partnerships within the industry [6][23]. - The company views centralized procurement as an opportunity for innovation, enabling faster dissemination of new products, as demonstrated by the rapid adoption of the Vivity lens [7][8]. - Alcon's participation in the China International Import Expo showcases its commitment to innovation, presenting a range of products and solutions that span the entire eye care process [8][9]. Group 3: Eye Care and Consumer Experience - Alcon's vision care division focuses on enhancing consumer experiences, addressing issues like myopia prevention and screen-related discomfort through innovative products [17][18]. - The company emphasizes the importance of brand trust and product safety in the contact lens market, aligning its marketing strategies with consumer education [19][20]. - Alcon aims to integrate professional and experiential education to build consumer confidence in its products, ensuring that innovation translates into everyday life [20][21]. Group 4: Global Innovation and Feedback - Alcon's innovation is increasingly driven by feedback from Chinese experts, demonstrating a shift from merely introducing innovations to co-creating them [23][24]. - The launch of the Wavelight Plus procedure in China highlights the country's leading role in refractive surgery research and its influence on global practices [25][26]. - Alcon envisions a future where innovations originating from China contribute significantly to the global eye health industry [26][27].

Summary of Conference Call Records Industry Overview - The pharmaceutical and healthcare sectors are currently experiencing a shift, with companies like沃伍生物, 方盛制药, and 佐力药业 showing strong stock performance and potential investment opportunities due to their solid revenue, profit, and cash flow [1][3] - The medical services industry is facing challenges due to DRG policies and a weak consumer environment, but improvements are expected by 2026 as supply-side constraints and potential mergers or new hospital openings may enhance performance metrics [1][4] Key Companies and Investment Opportunities - **Ophthalmology Sector**: Companies such as 爱尔, 华夏, and 普瑞 are recommended for investment, with expectations of performance release in refractive services by Q1 2026 and improvements in cataract screening next year [1][5] - **Dental Sector**: 通策医疗 is highlighted for its new hospital openings and expected revenue and profit growth in 2026, indicating a turning point for the company [1][6] - **Pharmaceutical Companies**: 流感-related companies like 国邦, 普洛药业, and 联邦制药 are experiencing high capacity utilization and are expected to see significant growth in Q4 and Q1 due to potential shortages and price increases [2][12] Market Trends and Predictions - The blood products industry is consolidating, with a focus on mergers and acquisitions, which may stabilize product prices and enhance demand in the context of flu outbreaks [8] - The vaccine industry is poised for growth with key players like 康华生物 and 康希诺 expected to release significant data and products in 2026, which could drive market interest [9][10] - The traditional Chinese medicine sector is forecasted to recover, with a focus on innovative drug companies and OTC brands that are well-positioned for growth [13] Retail Pharmacy Sector - The retail pharmacy sector is expected to benefit from consolidation as smaller chains face operational pressures, allowing leading companies like 益丰, 大森林, and 老百姓 to capitalize on improved consumer conditions and policy support [14] Conclusion - The overall sentiment in the pharmaceutical and healthcare sectors is cautiously optimistic, with several companies positioned for growth amid a backdrop of regulatory changes and market dynamics. Investors are encouraged to focus on companies with strong fundamentals and growth potential in the coming years [1][3][4][12][14]

Core Insights - The 8th China International Import Expo concluded with the launch of the "National Vision Health Report (2026 Edition)" led by Peking University, aiming to address vision health issues throughout the life cycle [1][2] - The report emphasizes the need for integrating preventive measures into public health and insurance systems, particularly for vision correction and screening services [1][3] Group 1: Vision Health Challenges - The prevalence of myopia in China is alarming, with approximately 600 million individuals affected, and the youth myopia rate is the highest globally [2] - There is a significant lack of public health policies addressing adult vision health issues, such as workplace dry eye syndrome and visual fatigue [1][2] - The economic burden of vision-related issues was estimated at 680 billion yuan in 2012, and this cost is expected to rise due to worsening eye health conditions [2] Group 2: Policy and Insurance Developments - There is a growing call to include vision screening and eyewear fitting in medical insurance, but current policies do not support this [3][4] - The Jiangsu Provincial Medical Security Bureau is exploring the inclusion of relevant diagnostic and treatment projects in the insurance coverage, aiming to alleviate the financial burden on insured individuals [4] - The National Medical Security Administration has issued guidelines focusing on pediatric myopia and amblyopia, promoting early diagnosis and treatment [4][5] Group 3: Regional Successes - Shanghai has successfully implemented a tiered approach to myopia prevention, resulting in a 1.5 percentage point decrease in myopia rates among children and adolescents from 2023 to 2024 [5] - The city's efforts align with the national health strategy, emphasizing early intervention and comprehensive care for vision health [5]